A prospective observational study on efficacy of ulipristal acetate in treatment of uterine fibroids

Eshna Singh; Vandana Khanijo; Jyothi Unni

doi:10.18203/2320-1770.ijrcog20242280

Authors

Eshna Singh Department of Obstetrics and Gynaecology, Jehangir Hospital, Pune, Maharashtra, India
Vandana Khanijo Department of Obstetrics and Gynaecology, Jehangir Hospital, Pune, Maharashtra, India
Jyothi Unni Department of Obstetrics and Gynaecology, Jehangir Hospital, Pune, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242280

Keywords:

Fibroids, UPA, PBAC, HMB

Abstract

Background: Uterine fibroids are common benign tumors where management has traditionally been surgical. Ulipristal acetate (UPA) is a new, effective, and well-tolerated option for the preoperative treatment of moderate and severe symptoms of uterine fibroids. Objectives were to study the utility of UPA in treatment of uterine fibroids.

Methods: A prospective observational study was conducted in women aged 18-50 years presenting with menstrual abnormalities with fibroids to Jehangir Hospital, from 01 December 2017 to 30 September 2019. The 50 premenopausal women with at least one fibroid ≥3 cm in diameter and <8 cm, with heavy menstrual bleeding (HMB) or pain were included. 5 mg of UPA was given once daily for a period 3 months. Primary outcome was to determine symptomatic relief.

Results: Uterine bleeding was controlled in 96% patients whereas 100% had pain relief. Reduction of fibroid volume and size was noted in 60% patients. Favourable outcomes were seen in more cases of intramural fibroids as compared to sub-serosal and submucosal fibroids.

Conclusions: UPA proved to be an effective drug for symptomatic relief in patients with uterine fibroids. Although 60% patients showed reduction in fibroid size, the amount of reduction was not very significant in most of the patients.

Metrics

Metrics Loading ...

References

Biglia N, Carinelli S, Maiorana A, D’Alonzo M, Lo Monte G, et al. Ulipristal Acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014;8:285-92.

Garg R. Two Uncommon Presentations of Cervical Fibroids. People’s J Scientific Res. 2012;5:36-9.

Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2018;46:3-11.

Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293-8.

Sohn GS, Cho S, Kim YM, Cho CH, Kim MR, Lee SR. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018:61(2):192-201.

Talaulikar V. Ulipristal Acetate: a novel medical therapy for uterine fibroids. J Obstet-Gynecol. 2014;24(8):254-5.

Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HJ, Zatik J, et al. Efficacy and safety of repeated use of Ulipristal Acetate in uterine fibroids. Fertil Steril. 2015;103(2):519-27.

Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F. PEARL II Study group. Ulipristal Acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421-32.

Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long term treatment of uterine fibroids with Ulipristal Acetate Fertil Steril. 2014;101(6):1565-73.e1-18.

Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T. Ulipristal Acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409-20.

Okolo S. Incidence, Aetiology and Epidemiology of Uterine Fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571-88.

Yu O, Scholes D, Schulze-Rath R, Grafton J, Hansen K, Reed SD. A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014. Am J Obstet Gynecol. 2018;219(591):1-8.

Terry KL, De Vivo I, Hankinson SE, Missmer SA. Reproductive characteristics and risk of uterine leiomyomata. Fertil Steril. 2010;94:2703.

Dolores F, Röhl FW, Friedrich C, Tylkoski H, Rabe T Römer T, et al. Symptoms of uterine myomas: data of an epidemiological study in Germany. Arch Gynecol Obstet. 2017;295(2):415-26.

Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women's Health. 2012;12(1):6.

Bochenska K, LeWitt T, Marsh EE, Pidaparti M, Mendoza G, Lewicky Gaupp C, et al. Fibroids and urinary symptoms study (FUSS). Am J Obstet Gynecol. 2017;216( 3):S617.

Khyade RL. A study of menstrual disturbances in fibroid uterus. Int J Reprod Contracept Obstet Gynecol. 2017 6(6):2494-7.

Esmya: new measures to minimise risk of rare but serious liver injury. European Med Agency. 2018.

Fernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. Eur J Obstet Gynecol Reprod Biol. 2017;208:91-6.

Giarrè G, Franchini M, Castellacci E, Malune ME, Di Spiezio Sardo A, Saccone G, et al. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study. Gynecol Endocrinol. 2019;36(2):71-4.

Woodhead N, Pounds R, Irani S, Pradhan P . Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. J Obstet Gynaecol. 2018;38(6):813-7.

Hong YH, Han SJ, Lee D, Kim SK, Jee BC. Adverse symptoms during shortterm use of ulipristal acetate in women with uterine myomas and/or adenomyosis. J Obstet Gynaecol Res. 2019;45(4):865-70.